Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside F2

A non-alcoholic, ginsenoside technology, applied in the field of ginsenoside F2 pharmaceutical composition, health functional food and feed composition, can solve the problems that the effect of ginsenoside has not been revealed

Inactive Publication Date: 2016-09-14
INTELLIGENT SYNTHETIC BIOLOGY CENT
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of ginsenoside F2 in the treatment of non-alcoholic liver disease has not been revealed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside F2
  • Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside F2
  • Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside F2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Embodiment 1. Preparation of Ginsenoside F2

[0068] The leaves and roots of other ginseng including Korean ginseng, American ginseng, and bamboo ginseng are put into 20 times the volume of 80% alcohol, extracted twice or more, and dried to obtain crude saponins. The crude saponin was redissolved in water and adsorbed to HP-20 resin, then washed with 100% water to remove sugar, and then washed once with 40% alcohol to preferentially remove protopanaxatriol (protopanaxatriol) Line of ginsenosides Re and Rg1. Thereafter, by washing with 80% alcohol, protopanaxadiol-based ginsenosides Rb1, Rb2, Rc, and Rd were eluted and dried to obtain the ginsenoside F2. The mixture of protopanaxadiol and ginsenosides was used as a substrate and reacted according to the method described in Korean Laid-Open Patent No. 2013-0134930 to obtain 70% or more of ginsenoside F2. Thereafter, if the ODS resin is used to absorb the ginsenoside F2 that will be used as a sample, and the alcohol of a...

Embodiment 2

[0069] Example 2: Confirmation of Fatty Liver Relief Effect

[0070] In order to confirm the fatty liver alleviating effect of ginsenoside F2, a mouse model fed a high-fat diet was used. Eight-week-old male mice (body weight 25-28 g) were continuously fed a high-fat diet for 12 weeks, and 250 mg / kg of ginsenoside F2 was orally administered to the mice five days a week.

[0071] Thereafter, the liver was isolated and observed, and the result was confirmed as follows: Compared with the control group, the size of the liver of the group using ginsenoside F2 ( Figure 1a ) and liver weight ( Figure 1b ) is significantly reduced. From these results, it can be seen that ginsenoside F2 has an effect of suppressing fatty liver even if a high-fat diet is performed.

Embodiment 3

[0072] Example 3: Liver tissue analysis

[0073] In order to observe the changes in the liver tissue of the mice carrying out the high-fat diet described in Example 2, perform H&E (Hematoxylin and eosin) staining, and stain the neutral lipids of the liver cells by Oil Red O (Oil Red O) staining, Express the results at a magnification of ×100 ( Figure 2a ). As a result, it was reconfirmed that the accumulation of fat in hepatocytes was reduced by the administration of ginsenoside F2.

[0074] In addition, it was confirmed that the value of neutral fat in the liver (Liver TG) decreased ( Figure 2b ), the protein expression of SREBP1c and FAS, which play an important role in fat synthesis, and the expression levels of CB1R, NAPE-PLD, SREBP1c and FAS genes decreased ( Figure 2c and Figure 2d ). Therefore, it was confirmed that ginsenoside F2 effectively suppresses fat formation in the liver.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-alpha, IL-beta, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

Description

technical field [0001] The invention relates to a pharmaceutical composition of ginsenoside F2 for preventing, improving or treating non-alcoholic liver disease or insulin resistance, a health functional food and a feed composition. Background technique [0002] The liver is a very important organ responsible for various metabolisms, detoxification, decomposition, synthesis and secretion in the human body. Its specific functions are as follows: First, the liver has the function of managing energy metabolism, metabolizing all nutrients absorbed from food It is a substance that can produce energy and supply or store it to the whole body. Second, the liver has the functions of synthesizing, storing and distributing fats such as about 2000 kinds of enzymes, albumin, blood coagulation factor serum protein, bile acid, phospholipid, cholesterol, etc. Third, the liver has the function of excreting various metabolites to the duodenum through the bile duct, and has immune functions, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P1/16A61P5/50A23L33/105A23K20/121
CPCA61K31/704A23V2002/00A23V2200/32A23V2200/328A23V2250/2124A61K31/7028A61P1/16A61P5/50A61P3/10A23K10/30A23L33/105A23V2200/30
Inventor 郑元日金善昌郑朱延林完泽
Owner INTELLIGENT SYNTHETIC BIOLOGY CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com